

8K Miles Software Services Ltd. (“8K Miles”) the leading provider of secure Cloud solutions today announced the acquisition of Clinical Research Software Startup – Mindprint Inc, Canada.


Chennai, March 9, 2015 -- 8K Miles Software Services Ltd, the leading provider of secure Cloud solutions today announced that its US Subsidiary 8K Miles Software Services Inc. has entered into an asset purchase agreement with Mindprint Inc. (“Mindprint”), a clinical research software startup focused on analytics and operational software for Clinical Research Organizations (CROs) and Pharmaceutical Sponsors. This asset purchase agreement includes acquisitions of intellectual property, client contracts and employees. The total consideration in cash and stock, for the acquisition is \$400,000 dollars (\$150,000 in cash and \$250,000 worth of US subsidiary stock).

Large Enterprise customers from verticals markets, such as: Healthcare, Pharmaceutical, Financial and Insurance that have primary focus on security and compliance - rely on 8K Miles’ trusted Cloud offerings. Mindprint’s deep domain knowledge of CRO and pharmaceutical outsourcing operations provides 8K Miles with additional competitive advantage for successfully entering into the CRO market and in order to capitalize on its growth potential.

“According to the TechNavio's analysts forecast - the Global CRO market will grow at a CAGR of 9.83 percent over the period 2014-2019," said Suresh Venkatachari, Chairman and CEO of 8K Miles. "This acquisition is yet another demonstration of 8K Miles’ commitment to the Pharmaceutical vertical market."

Global CROs use Mindprint SaaS analytics and operational software to gain valuable insights into their profitability, resource utilization, study progress and forecasts. Mindprint has announced multiple highly successful client implementations of their SaaS software systems ranging from small to mid-size CROs.

"Working with the Mindprint team was a pleasure. They have a solid understanding of CRO operations and helped to refine our processes using their software," said Jeff Burdine, Director of IT Commercial Systems at Chiltern. "Mindprint's software played a key role in the integration of Ockham and Nexus Oncology."



With this acquisition of Mindprint by 8K Miles, Prasad A. Sristi, President of Mindprint Inc. will take on the role of VP, Product Management and Business Development at 8K Miles. The deal is effective immediately.

"We are very excited to become an integral part of the 8K Miles success in the CRO market," said Prasad A. Sristi. "8K Miles' culture of entrepreneurship is very impressive. Their operations, sales, and marketing expertise provide a strong platform for us to continue to build the Mindprint innovation even further. Our common competencies enable us to broaden our reach and strengthen existing partner relationships, while we extend greater value within our client base."

The transaction is expected to close before March 31, 2015, subject to customary closing conditions.

About 8K Miles Software Services (www.8kmiles.com):

8K Miles Software Services is a global Cloud & Security solutions company headquartered in the San Francisco Bay area and a publicly traded company listed on Indian Stock Exchanges (NSE and BSE). 8KMiles Software Services provides digital technology solutions – SMAC (Social, Mobile, Analytics and Cloud) for seamless connectivity between consumers, SMBs, enterprises and government agencies secured with EzIAM™ SaaS offering and our patented MISP™ platform for accelerated Business Partner federations.

About Mindprint (www.mindprintsolutions.com):

Mindprint Inc. specializes in providing SaaS analytics and operational software to Clinical Research Organizations and Pharmaceutical companies based in Markham, Ontario, Canada.. Mindprint brings clarity and transparency to its clients as they benefit from increased profitability, better predictability, streamlined business processes, and superior customer value. Mindprint has partnered with a number of leading CROs and understands the life cycle of a clinical study as well as the business challenges unique to the life sciences industry.



R S Ramani
Whole Time Director